Bringing gut microbiota into the spotlight of clinical research and medical practice  

作　　者：Efstathia Davoutis Zoi Gkiafi Panagis M Lykoudis 

机构地区：[1]School of Medicine,National and Kapodistrian University of Athens,Athens 11527,Greece [2]Division of Surgery and Interventional Science,University College London,London WC1E 6BT,United Kingdom

出　　处：《World Journal of Clinical Cases》2024年第14期2293-2300,共8页世界临床病例杂志

摘　　要：Despite the increasing scientific interest and expanding role of gut microbiota(GM)in human health,it is rarely reported in case reports and deployed in cli-nical practice.Proteins and metabolites produced by microbiota contribute to im-mune system development,energy homeostasis and digestion.Exo-and endoge-nous factors can alter its composition.Disturbance of microbiota,also known as dysbiosis,is associated with various pathological conditions.Specific bacterial taxa and related metabolites are involved in disease pathogenesis and therefore can serve as a diagnostic tool.GM could also be a useful prognostic factor by predicting future disease onset and preventing hospital-associated infections.Ad-ditionally,it can influence response to treatments,including those for cancers,by altering drug bioavailability.A thorough understanding of its function has per-mitted significant development in therapeutics,such as probiotics and fecal trans-plantation.Hence,GM should be considered as a ground-breaking biological parameter,and it is advisable to be investigated and reported in literature in a more consistent and systematic way.

关 键 词：Gut microbiota BIOMARKER Fecal microbiota transplantation DYSBIOSIS PREBIOTICS 

分 类 号：R57[医药卫生—消化系统]